Day 1, Session III

Early-Stage Drug Pipeline: Proof of Principle through IND.
Moderated by Roger J. Porter, MD, Chief Scientific Officer, Epilepsy Foundation

 

This session includes:

  • Intellimedix | Platform of Computational, In-Silico Screening, and Then Hi-thru Put Testing in Zebra Fish With an Initial Focus on Dravet but Broad Focus on Epilepsy.
    Jeffrey Skolnick, PhD, Scientific Advisor, Intellimedix, Director of the Integrated Biosystems Institute at Georgia Institute of Technology
    Starts at: 1:30
     
  • Asklepios BioPharmaceutical, Inc. | Galanin Gene Delivery for Temporal Lobe Epilepsy
    Cynthia Rask, MD, CMO, Asklepios BioPharmaceutical, Inc.
    Starts at: 11:49
     
  • AurimMed Pharma, Inc. | AMP-X-0079
    Amir Pesyan, Chairman and CEO, AurimMed Pharma, Inc.
    Starts at: 19:34
     
  • BioCrea | LT GABA PAMS for Refractory Epilepy
    Norbert Hoefgen, PhD, VP Discovery, BioCrea
    Starts at: 23:00
     
  • EpaleX | Inhaled Treatment for Refractory Epilepsy
    Michael A. Rogawski, MD, PhD, Professor, Department of Neurology, University of California, Davis
    Presentation removed at presenter's request
     
  • Fluorinov Pharma Inc. | FV-082: A Safer Orally Active Broad Spectrum Anti-Epileptic Drug Candidate
    Malik Slassi, PhD, President and CSO, Fluorinov Pharma Inc.
    Starts at: 36:00
     
  • NeuroGate Therapeutics, Inc. | Extended NeuroAmides
    Harold Kohn, PhD, Kenan Distinguished Professor, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy and Department of Chemistry University of North Carolina – Chapel Hill, and Founder, NeuroGate Therapeutics, Inc.
    Starts at: 47:57
     
  • NeuroGenomeX, Inc. | 2DG
    Thomas P. Sutula, MD, PhD, Founder, CTO and Director, NeuroGenomeX, Inc.
    Starts at: 57:00
     
  • INSYS Therapeutics, Inc. | Synthetic CBD
    Mark Davis, Senior Director Clinical
    Starts at: 1:08:01
     
  • NeuroAdjuvants, Inc. | Galanin Receptor 2-Based Therapy
    H. Steve White, PhD, Professor and Director, Anticonvulsant Drug Development Program, University of Utah
    Starts at: 1:15:15
     
  • University of South Florida | Ketogenic Compounds for the Treatment of Epilepsy
    Dominic D'Agostino, PhD, Assistant Professor, Hyperbaric Biomedical Research Laboratory
    Starts at: 1:24:13
     
  • SciFluor Life Sciences LLC | KCNQ2/3
    D. Scott Edwards, Vice President and General Manager
    Starts at: 1:33:45
     
  • Sage Therapeutics | Development of Programs for Status Epilepticus
    Jeffrey Jonas, MD, CEO, Sage Therapeutics
    Starts at: 1:46:14

<< Previous Video:
Day 1, Introduction and Keynote Addresses, and What Was Better in 2013 than 2012-Progress in Epilepsy Therapy

>> Next Video:
Day 1, Early-Stage Diagnostic Devices and Product Pipeline: New Concepts and Initial Findings

ADVERTISEMENT
2014 Epilepsy Pipeline Conference

On June 5-7, 2014 in San Francisco, CA, the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation presented the 4th Biennial Epilepsy Pipeline Conference 2014, held at the Hyatt Regency, San Francisco.

Showcasing the most promising epilepsy therapies from healthcare companies dedicated to pioneering and advancing drugs, biologics, technologies and devices for epilepsy and seizures, this year's conference featured the third annual "Shark Tank" competition, in addition to a day designated for people with epilepsy, families and advocates. The conference brought together decision-makers with a stake in the field of epilepsy treatment, therapeutic innovation and product development. Speakers and attendees included emerging biotech and medical technology companies, major pharmaceutical and device companies, and researchers and innovators at the cutting-edge of epilepsy and CNS treatment advances.

Read the press release for more information

ADVERTISEMENT